BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27251951)

  • 1. Modification of the pT2 substage classification in prostate adenocarcinoma.
    Ettel M; Kong M; Lee P; Zhou M; Melamed J; Deng FM
    Hum Pathol; 2016 Oct; 56():57-63. PubMed ID: 27251951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ; Partin AW; Epstein JI; Walsh PC
    Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens.
    Epstein JI
    J Urol; 2011 Sep; 186(3):790-7. PubMed ID: 21788055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
    Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
    J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
    Antunes HP; Parada B; Carvalho J; Eliseu M; Jarimba R; Oliveira R; Tavares-da-Silva E; Figueiredo A
    Arch Ital Urol Androl; 2018 Sep; 90(3):191-194. PubMed ID: 30362685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy.
    May F; Hartung R; Breul J
    BJU Int; 2001 Nov; 88(7):702-7. PubMed ID: 11890240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
    Nguyen DP; Vertosick EA; Sharma V; Corradi RB; Vilaseca A; Takeda T; Sjoberg DD; Benfante N; Fine SW; Reuter VE; Scardino PT; Eastham JA; Karnes RJ; Touijer KA
    J Urol; 2018 Jun; 199(6):1502-1509. PubMed ID: 29307681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume.
    van der Kwast TH; Amin MB; Billis A; Epstein JI; Griffiths D; Humphrey PA; Montironi R; Wheeler TM; Srigley JR; Egevad L; Delahunt B;
    Mod Pathol; 2011 Jan; 24(1):16-25. PubMed ID: 20818340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.
    Chun FK; Briganti A; Lebeau T; Fradet V; Steuber T; Walz J; Schlomm T; Eichelberg C; Haese A; Erbersdobler A; McCormack M; Perrotte P; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2006 Feb; 49(2):273-8; discussion 278-9. PubMed ID: 16413103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer.
    Choi SY; Chi BH; Lim B; Kyung YS; You D; Jeong IG; Song C; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):537-543. PubMed ID: 31915914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy.
    DeCastro GJ; McCann T; Benson MC; McKiernan JM
    Urology; 2008 Dec; 72(6):1214-8. PubMed ID: 18597825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?
    Billis A; Meirelles LL; Freitas LL; Magna LA; Reis LO; Ferreira U
    Int Urol Nephrol; 2011 Sep; 43(3):707-14. PubMed ID: 21336958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages - Does extent of tumor involvement matter?
    Pompe RS; Neumann T; Kühnke L; Preisser F; Gild P; Tennstedt P; Salomon G; Huland H; Tilki D
    Urol Oncol; 2020 Jul; 38(7):637.e1-637.e7. PubMed ID: 32245678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
    Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
    BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
    Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
    Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclassification of pathologically organ-confined (pT2) prostate cancer does not significantly predict postoperative outcomes in Korean males.
    Lee MH; Lee S; Hong SK; Byun SS; Lee SE
    Investig Clin Urol; 2020 Jan; 61(1):35-41. PubMed ID: 31942461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific spatial distribution patterns of tumor foci are associated with a low risk of biochemical recurrence in pT2pN0R0 prostate cancer.
    Eminaga O; Abbas M; Bettendorf O; Semjonow A
    World J Urol; 2021 May; 39(5):1499-1507. PubMed ID: 32591903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy?
    Augustin H; Hammerer PG; Blonski J; Graefen M; Palisaar J; Daghofer F; Huland H; Erbersdobler A
    Urology; 2003 Jul; 62(1):79-85. PubMed ID: 12837427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.